Cargando…

Overview of Cellular Immunotherapy for Patients with Glioblastoma

High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vauleon, Elodie, Avril, Tony, Collet, Brigitte, Mosser, Jean, Quillien, Véronique
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952949/ https://www.ncbi.nlm.nih.gov/pubmed/20953324 http://dx.doi.org/10.1155/2010/689171

Ejemplares similares

Immune genes are associated with human glioblastoma pathology and patient survival
por: Vauléon, Elodie, et al.
Publicado: (2012)

Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach
por: Collet, Brigitte, et al.
Publicado: (2011)

Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2019)

DNA methylation in glioblastoma: impact on gene expression and clinical outcome
por: Etcheverry, Amandine, et al.
Publicado: (2010)

The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line
por: Monnier, Annabelle, et al.
Publicado: (2018)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Dual IRE1 RNase functions dictate glioblastoma development
por: Lhomond, Stéphanie, et al.
Publicado: (2018)

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2014)

Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme
por: Xu, Xun, et al.
Publicado: (2012)

Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
por: Avril, T, et al.
Publicado: (2017)

Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario
por: Bianconi, Andrea, et al.
Publicado: (2023)

Immunotherapy for glioblastoma: the promise of combination strategies
por: Bausart, Mathilde, et al.
Publicado: (2022)

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial
por: Quillien, Véronique, et al.
Publicado: (2016)

Prognostic Significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, Four New Markers in High-Grade Gliomas
por: de Tayrac, Marie, et al.
Publicado: (2013)

Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases
por: Tešić, Nataša, et al.
Publicado: (2021)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

MicroRNA in Glioblastoma: An Overview
por: Banelli, Barbara, et al.
Publicado: (2017)

Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019)

Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Advances in Immunotherapy for Adult Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2021)

Next Steps for Immunotherapy in Glioblastoma
por: Cao, Toni Q., et al.
Publicado: (2022)

Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Advances in immunotherapy for the treatment of glioblastoma
por: Tivnan, Amanda, et al.
Publicado: (2016)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Immunotherapy in Glioblastoma: A Clinical Perspective
por: Desbaillets, Nicolas, et al.
Publicado: (2021)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Natural killer cell immunotherapy in glioblastoma
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
por: Liu, Xudong, et al.
Publicado: (2023)

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
por: Tan, Wei Chang Colin, et al.
Publicado: (2020)

Cellular Immunotherapy and the Lung
por: Daly, Sorcha, et al.
Publicado: (2021)

Cellular immunotherapy for medulloblastoma
por: Schakelaar, Michael Y, et al.
Publicado: (2022)

Glioblastoma Microenvironment and Cellular Interactions
por: Crivii, Carmen-Bianca, et al.
Publicado: (2022)

Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
por: Ahn, Jaehyun, et al.
Publicado: (2022)

Radiation Therapy for the Treatment of Recurrent Glioblastoma: An Overview
por: Amelio, Dante, et al.
Publicado: (2012)

Cellular immunotherapies for cancer
por: Hayes, Conall
Publicado: (2020)

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
por: Amelot, Aymeric, et al.
Publicado: (2015)

Immunocompetent murine models for the study of glioblastoma immunotherapy
por: Oh, Taemin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bth8ebhgvsgjpbukk46jvv57k4